Patents by Inventor Wolfgang Axel Tome
Wolfgang Axel Tome has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230310610Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt therof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: ApplicationFiled: February 27, 2023Publication date: October 5, 2023Inventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Patent number: 11623007Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt therof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: GrantFiled: September 25, 2020Date of Patent: April 11, 2023Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Publication number: 20210008203Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt therof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: ApplicationFiled: September 25, 2020Publication date: January 14, 2021Inventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Patent number: 10813998Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: GrantFiled: February 26, 2019Date of Patent: October 27, 2020Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Publication number: 20190184014Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: ApplicationFiled: February 26, 2019Publication date: June 20, 2019Inventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Patent number: 10265398Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: GrantFiled: November 4, 2016Date of Patent: April 23, 2019Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tomé
-
Publication number: 20170128572Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: ApplicationFiled: November 4, 2016Publication date: May 11, 2017Inventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tomé
-
Patent number: 8897857Abstract: A method of producing a patient image indicating proton stopping power of the tissue may employ photon attenuation information converted to proton stopping power. The conversion uses different conversion functions for particular tissue types to account for a strong atomic number dependency in the conversion process. Megavoltage x-rays may be used for improved accuracy.Type: GrantFiled: October 31, 2011Date of Patent: November 25, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Wolfgang Axel Tomé, Dongxu Wang, Thomas R. Mackie
-
Patent number: 8526692Abstract: Deformation maps (e.g. deformation vector fields) used for correcting image-type data used in the treatment of patients in radiotherapy may be processed to eliminate inverse inconsistency and transitivity type errors which produce different results depending on the order or path of the calculation of deformation. The correction permits registration of a treatment plan with the changing patient image and accumulation of dose to a common reference frame without transformation dependent artifacts.Type: GrantFiled: June 30, 2011Date of Patent: September 3, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Wolfgang Axel Tomé, Edward Thomas Bender, Nicholas Gordon Lance Hardcastle
-
Publication number: 20130108014Abstract: A method of producing a patient image indicating proton stopping power of the tissue may employ photon attenuation information converted to proton stopping power. The conversion uses different conversion functions for particular tissue types to account for a strong atomic number dependency in the conversion process. Megavoltage x-rays may be used for improved accuracy.Type: ApplicationFiled: October 31, 2011Publication date: May 2, 2013Inventors: Wolfgang Axel Tomé, Dongxu Wang, Thomas R. Mackie
-
Publication number: 20130004034Abstract: Deformation maps (e.g. deformation vector fields) used for correcting image-type data used in the treatment of patients in radiotherapy may be processed to eliminate inverse inconsistency and transitivity type errors which produce different results depending on the order or path of the calculation of deformation. The correction permits registration of a treatment plan with the changing patient image and accumulation of dose to a common reference frame without transformation dependent artifacts.Type: ApplicationFiled: June 30, 2011Publication date: January 3, 2013Inventors: Wolfgang Axel Tomé, Edward Thomas Bender, Nicholas Gordon Lance Hardcastle
-
Patent number: 7551717Abstract: A virtual 4D treatment suite includes a dose calculation module, a gating module, and a dose rate adjustment module. The 4D treatment suite may be used to virtually analyze the impact the motion of a target tissue has on therapy for a particular patient and a proposed treatment plan. For example, for a proposed treatment plan, the dose calculation module may calculate a dose that would be received by a target tissue and an associated dose temporal variation based on an identified movement of the target tissue relative to at least a portion of a treatment field. Based on the calculated expected therapy dose and dose temporal variation, the gating module may determine whether to implement a gating technique for the proposed treatment plan and/or the dose rate adjustment module may determine whether to adjust the dose rate of the proposed treatment plan.Type: GrantFiled: August 21, 2007Date of Patent: June 23, 2009Assignees: Wisconsin Alumni Research Foundation, Koninklijke Philips Electronics NVInventors: Wolfgang Axel Tomé, Eric Drew Ehler
-
Publication number: 20090052623Abstract: A virtual 4D treatment suite includes a dose calculation module, a gating module, and a dose rate adjustment module. The 4D treatment suite may be used to virtually analyze the impact the motion of a target tissue has on therapy for a particular patient and a proposed treatment plan. For example, for a proposed treatment plan, the dose calculation module may calculate a dose that would be received by a target tissue and an associated dose temporal variation based on an identified movement of the target tissue relative to at least a portion of a treatment field. Based on the calculated expected therapy dose and dose temporal variation, the gating module may determine whether to implement a gating technique for the proposed treatment plan and/or the dose rate adjustment module may determine whether to adjust the dose rate of the proposed treatment plan.Type: ApplicationFiled: August 21, 2007Publication date: February 26, 2009Applicant: Wisconsin Alumni Research FoundationInventors: Wolfgang Axel Tome, Eric Drew Ehler